|
|
|
|
|
Session 4
Opening Plenary and Keynote Session Bernard Fields Memorial Lecture Tuesday, 6 - 8 pm Presentation Time: 6:15 pm Auditorium |
Work from a number of groups in the past three
years has demonstrated that the cellular polynucleotide cytidine deaminases
APOBEC3G and APOBEC3F are potent inhibitors of HIV infection. As such, they constitute a new form of
innate, host-mediated resistance to viral infection. In the absence of the viral Vif protein,
these enzymes are encapsidated by budding virus particles and then transferred
to target cells where they catalyse the excessive
deamination of cytidine (C) to uridine (U) in first strand reverse transcripts
(or cDNAs). This results in both guanosine (G) to adenosine (A) hypermutation of viral plus
stranded cDNA and an overall diminution in the accumulation of viral
cDNAs. Together, these effects
contribute to the very low infectivity of viruses produced in the absence of
Vif, but in the presence of APOBEC3G/F.
Vif protects HIV from these enzymes through the recruitment of cellular
ubiquitin ligases, which then trigger their elimination by the proteasome. One current view of the opposing activities
of Vif and the APOBEC3G/F proteins during natural infection is that they are in
are in “equilibrium” with each other.
Accordingly, increases in APOBEC protein function or levels, or
interference with Vif function, could culminate in increases in mutation rates
that could either confer selective advantages upon viral populations or, at
more extreme levels, result in losses to virus infectivity and/or increases in
G-to-A hypermutation. Sequencing of
viruses during natural infection indicates that the latter can indeed occur,
thus suggesting that perturbation of Vif/APOBEC function deserves consideration
as a future therapeutic strategy.
|